Diabetes, a major cause of morbidity and mortality in the United States and the leading cause of new cases of blindness in adults, affects more than 25 million people, or 8.3% of the population.1 Currently, only 60% of persons with diabetes receive standard-of-care screening examinations for retinopathy, and the number is even lower in the safety net.2,3 Given that the projected increase in the prevalence of diabetes will increase the demand for screening examinations, we must identify alternative ways to screen for diabetic retinopathy (DR).